Atorvastatin and Pravastatin Elevated Pre-heparin Lipoprotein Lipase Mass of Type 2 Diabetes with Hypercholesterolemia

Abstract

To clarify whether 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin) increases lipoprotein lipase mass in preheparin plasma (preheparin LPL mass), we observed the change in preheparin LPL mass during administration of atorvastatin and pravastatin to type 2 diabetes mellitus patients with hypercholesterolemia. The subjects were randomly divided into two groups. One group was 24 patients given atorvastatin (10 mg/day), and the other was 23 patients given pravastatin (20 mg/day) for 4 months. After 4 months of administration, no significant change of HbA1c was observed. TC significantly decreased in the atorvastatin group compared to the pravastatin group. TG significantly decreased in the atorvastatin group. Low density lipoprotein cholesterol level significantly decreased in both groups (- 36.3%, p < 0.01 in atorvastatin, - 24.3%, p < 0.01 in pravastatin). Preheparin LPL mass slightly increased in both groups after 4 months of administration. Especially in patients who showed low preheparin LPL mass (less than 50 ng/ml) before statin administration, preheparin LPL mass significantly increased in both groups (+ 25.8% in the atorvastatin group, + 24.39% in the pravastatin group). These results suggested that administration of atorvastatin and pravastatin to type 2 diabetic patients with hypercholesterolemia increased serum preheparin LPL mass concentration. Especially, its effect was remarkable in patients who showed low preheparin LPL mass.

Serum lipoprotein lipase mass: Clinical significance of its measurement

“…This observation has been in line with the previous reports on the effects of this compound on LPL activity in PHP [45,46]. Recently, it has been reported that series of statins, such as pravastatins, atorvastatins and pitavastatins may produce a significant increase in serum LPL mass after the treatment [47,48]. An in vitro study has shown that that pitavastatins increase the expression of LPL mRNA from cultured 3T3 L1 cells [47].…”

Exercise training prevents skeletal muscle plasma membrane cholesterol accumulation, cortical actin filament loss, and insulin resistance in C57BL/6J mice fed a western-style high-fat diet

“…Notably, statins increase LPL serum mass and activity in T2D (Endo et al. 2004). Perhaps these findings offer some explanation as to why some statins increase, albeit modestly, the risk of T2D(Thakker et al.…”

Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts

“…21 Administration of the potent statins simvastatin or atorvastatin to humans with hyperlipidemia and/or diabetes led to increases in preheparin LPL mass or post-heparin LPL activity in three out of four studies. [22][23][24][25] The weaker statin fluvastatin did not alter LPL activity in dyslipidemic subjects. 26 Given this evidence of statin modulation of LPL activity, the LPL haplotypes we analyzed may affect lipid response to statin by altering the responsiveness of LPL expression or activity to statins.…”